Tratamento de Tumores Neuroendócrinos Gastroenteropancreáticos com 177Lu-DOTA-TATE: Experiência do Instituto Português de Oncologia do Porto

Tratamento de Tumores Neuroendócrinos Gastroenteropancreáticos com 177Lu-DOTA-TATE: Experiência do Instituto Português de Oncologia do Porto

Introdução: O objetivo deste artigo é rever a experiência do Instituto Português de Oncologia do Porto na terapêutica de tumores neuroendócrinos gastroenteropancreáticos com 177Lu-DOTA-TATE, tendo como principais pontos de análise a segurança e eficácia terapêutica. Material e Métodos: Foi realizad...

Full description

Bibliographic Details
Main Authors:	Inês Lucena Sampaio, Henrique Vara Luiz, Liliana Sobral Violante, Ana Paula Santos, Luís Antunes, Isabel Torres, Cristina Sanches, Isabel Azevedo, Hugo Duarte
Format:	Article
Language:	English
Published:	Ordem dos Médicos 2016-11-01
Series:	Acta Médica Portuguesa
Subjects:	177Lu-DOTATATE Neoplasias Gastrointestinais Neoplasias do Pâncreas Tumores Neuroendócrinos.
Online Access:	https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/7306

Similar Items

Errata ao artigo “Tratamento de Tumores Neuroendócrinos Gastroenteropancreáticos com 177Lu-DOTA-TATE: Experiência do Instituto Português de Oncologia do Porto”, por Inês Lucena Sampaio, Henrique Vara Luiz, Liliana Sobral Violante, Ana Paula Santos, Luís Antunes, Isabel Torres, Cristina Sanches, Isabel Azevedo, Hugo Duarte publicado em Acta Med Port 2016 Nov;29(11):726-733
by: Inês Lucena Sampaio, et al.
Published: (2020-01-01)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [177Lu]Lu-DOTA-TATE therapy
by: Sriram Gubbi, et al.
Published: (2023-10-01)

Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
by: Madhav Prasad Yadav, et al.
Published: (2019-02-01)

Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE
by: Teresa Monserrat Fuertes, et al.
Published: (2023-09-01)

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour
by: Sejin Ha, et al.
Published: (2024-02-01)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01)

Dealing with dry waste disposal issues associated with 177mLu impurities: a long-term challenge for nuclear medicine departments
by: Sylviane Prevot, et al.
Published: (2023-01-01)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
by: Peter Frøhlich Staanum, et al.
Published: (2021-11-01)

Lymphopenia during 177Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report
by: Sarah Boughdad, et al.
Published: (2022-12-01)

Research Progress of 177Lu-DOTATATE in the Treatment of Neuroendocrine Tumor Patients with Environmental Radiation Safety
by: MA Guangyu;BA Jiantao;PENG Cheng;CHEN Yingmao
Published: (2022-04-01)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01)

Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry
by: Mercedes Riveira-Martin, et al.
Published: (2023-11-01)

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups
by: S. Vosoughi, et al.
Published: (2020-11-01)

Peptide Receptor Radionuclide Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
by: Maria I. del Olmo-García, et al.
Published: (2022-01-01)

Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
by: Matthew Glover, et al.
Published: (2021-11-01)

Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
by: Martyn E. Caplin
Published: (2021-11-01)

Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01)

Somatostatin receptor saturation after administration of high peptide amounts of [177Lu]Lu-HA-DOTATATE: when enough is enough
by: Hinke Siebinga, et al.
Published: (2022-12-01)

A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N
by: Fredrik Sundquist, et al.
Published: (2022-03-01)

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
by: Hinke Siebinga, et al.
Published: (2023-08-01)

Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for $$^{177}$$ 177 Lu-DOTATATE therapy
by: Laure Vergnaud, et al.
Published: (2022-05-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
by: Mattias Sandström, et al.
Published: (2020-12-01)

Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
by: Keamogetswe Ramonaheng, et al.
Published: (2022-07-01)

Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE
by: Javian C. Malcolm, et al.
Published: (2022-03-01)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01)

The Accuracy of TIAC Calculated Using SPECT/CT Imaging Data at 36- and 100-Hours Post Injection and Prior Information in 177Lu-DOTATATE
by: Rizka Mutik Siyami, et al.
Published: (2023-11-01)

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report
by: Alexis Huot Daneault, et al.
Published: (2021-07-01)

Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate
by: Arman Romiani, et al.
Published: (2021-08-01)

[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
by: Madhav Prasad Yadav, et al.
Published: (2020-10-01)

Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer
by: Xin-yuan Yu, et al.
Published: (2023-12-01)

Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy
by: Delphine Vallot, et al.
Published: (2024-04-01)

Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis
by: Jiao Ma, et al.
Published: (2022-11-01)

Optimizing the Schedule of PARP Inhibitors in Combination with <sup>177</sup>Lu-DOTATATE: A Dosimetry Rationale
by: Andreas Hallqvist, et al.
Published: (2021-10-01)

Evaluation of Human Absorbed Dose of 177Lu-DOTA-Trastuzumab Based on its Biodistribution Studies in Rats
by: A Bahrami-Samani, et al.
Published: (2016-08-01)

Tumor neuroendocrino y terapia con lutecio
by: Patricia Agüero, et al.
Published: (2021-12-01)

Correlations between [<sup>68</sup>Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Ragnar Bruvoll, et al.
Published: (2023-02-01)

Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
by: Johan Spetz, et al.
Published: (2017-08-01)

Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery
by: Else A. Aalbersberg, et al.
Published: (2022-09-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)